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Abstract 
Granulocyte and monocyte adsorptive apheresis (GMA) is reportedly useful as induction 
therapy for Crohn’s disease (CD). However, the effects of GMA on CD64 have not been well 
characterized. We report here our assessment of CD64 expression on neutrophils before and 
after treatment with GMA in two patients with CD. The severity of CD was assessed with the 
CD activity index (CDAI). The duration of each GMA session was 60 min at a flow rate of 
30 ml/min as per protocol. CD64 expression on neutrophils was measured by analyzing 
whole blood with a FACScan flow cytometer. In case 1, CD64 levels after each session of 
GMA tended to decrease compared to pretreatment levels, whereas in case 2, CD64 levels 
dropped significantly after treatment. The CDAI decreased after GMA in both cases 1 and 2. 
A significant correlation was noted between CDAI scores and CD64 levels in both cases. In 
conclusion, GMA reduced blood CD64 levels, which would be an important factor for the 
decrease of CDAI scores. 
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Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal 
tract that is characterized by recurrent inflammation at any location along its length 
[1]. Despite the advent of immunomodulatory therapies such as azathioprine and 
6-mercaptopurine, approximately 75% of CD patients require intestinal resection 
for complications related to stricturing or penetrating disease [2]. CD is associated 
with a Th1 immune response in which Th1 cells secrete tumor necrosis factor α 
(TNF-α) [3]. TNF-α, a proinflammatory cytokine that plays an important role in 
CD pathogenesis, can be upregulated by interleukin 1 (IL-1) and granulocyte 
macrophage colony-stimulating factor [4]. Infliximab (IFX) treatment has been 
shown to significantly reduce plasma CD40 levels and to reduce the number of 
activated Th1 cells in the peripheral blood and mucosa [5]. 
In studies of blood returned to patients from the outflow of a granulocyte and 
monocyte adsorptive apheresis (GMA) column, it was found that T-regulated cytokines 
such as IL-10 and TGF-β1 were elevated while proinflammatory cytokines such as 
interferon-γ (IFN-γ) were not. This action of GMA is potentially very interesting in 
patients with immune disorders, such as CD patients [6]. 
The clinical efficacy of GMA on inflammatory bowel disease (IBD) and related 
extraintestinal manifestations has been associated with an expansion of circulating 
CD4+ CD25+ Tregs and higher expression of FoxP3 in CD4+ T cells [7]. Accordingly, 
elevated CD4+ CD25+ FoxP3 may be a valuable index of remission in patients with 
IBD and other chronic relapsing-remitting inflammatory conditions during treatment 
with GMA [8]. Thus, GMA could be useful for CD patients as it improves the CD activity 
index (CDAI) [9]. However, the influence of GMA on CD64 levels has not been well 




A 27-year-old woman had been diagnosed with CD. She was steroid-refractory or -dependent for 
3 years, and IFX and adalimumab were administered. However, she did not achieve remission after 
anti-TNF-α treatment. Thus, GMA was selected for therapy for her CD. After 5 sessions of GMA once a 
week, her abdominal symptoms and defecation were improved. Blood CD64 was examined before and 
after GMA, and CDAI was assessed before each GMA session. No adverse effects of GMA were 
observed. 
Case 2 
A 37-year-old woman was diagnosed with CD. She was administrated IFX every 8 weeks. However, 
she did not also achieve remission after IFX treatment. Then GMA was selected for therapy for her CD. 
After 6 total sessions of GMA, her abdominal symptoms and defecation were improved. Blood CD64 
was examined before and after GMA, and CDAI was also assessed before each GMA session. No 
adverse effects of GMA were observed. 
Methods 
Two CD patients (both women, 27 and 37 years old) were enrolled, and CDAI was assessed as 
previously described [10]. GMA treatment was performed as a previously described [11]. Briefly,  
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Adacolumns and blood circuit lines were primed with sterile saline to remove air bubbles from the 
column and flow lines, and a second priming of the system was carried out with heparinized saline. 
Blood access was through the antecubital vein in one arm. The outflow blood was returned to the 
patient through the antecubital vein in the contralateral arm. The duration of each GMA session was 
60 min at a flow rate of 30 ml/min as per protocol. Each patient was treated with a GMA session once 
per week, and this continued for 5 or 6 weeks. With respect to CD status, each patient was evaluated 
by CDAI at screening, baseline, and then before each GMA session. 
Peripheral venous blood was obtained within 5 min of starting GMA and 5 min after completing 
each GMA session. CD64 expression on neutrophils was measured by staining whole blood with 
QuantiBrite CD64PE/CD45PerCP (Beckton-Dickinson, San Jose, Calif., USA) according to the 
manufacturer’s instructions. Briefly, 20 μl of QuantiBrite CD64PE/CD45PerCP was added to 50 μl of 
whole blood and incubated for 60 min in the dark at room temperature. This was followed by lysis of 
red blood cells with 2 ml of 1× FACSTM lysing solution without washing, followed by an additional 
60 min incubation to reduce nonspecific background staining [12]. These specimens were analyzed 
using a FACScan flow cytometer (Beckton-Dickinson) calibrated with QuantiBrite PE beads 
(Beckton-Dickinson). The QuantiBrite PE beads contain four different beads with known numbers of 
phycoerythrin (PE) molecules that make it possible to create a standard curve for determining the 
mean number of PE molecules present on a cell. As the CD64-PE antibody has been designed to bind 
one PE molecule per antibody, the mean number of CD64 molecules expressed on cells can be 
calculated using the PE fluorescence quantification kit with QuantiBrite PE beads. The three different 
cell populations (lymphocytes, monocytes and granulocytes) were identified and gated by CD45 vs. 
side scatter profile. 
CD64 and CDAI data are expressed as means ± standard deviation. Statistical analyses comparing 
the CD64 data of the two groups before and after GMA treatment were performed using paired 
Student’s t test. Correlation coefficients were assessed by linear regression analysis. A p value <0.05 
was considered to be statistically significant. 
Results 
In case 1, CD64 levels before GMA averaged 12,156.2 ± 2,301.1 molecules/cell, and 
the average value decreased to 11,855.8 ± 2,616.8 molecules/cell after GMA (p = 0.31). 
In case 2, CD64 levels before GMA were 5,080.5 ± 816.3 molecules/cell, and this 
decreased to 4,744.0 ± 815.7 molecules/cell after GMA (p = 0.02). Thus, CD64 levels 
were significantly decreased after GMA treatment compared to pretreatment levels in 
case 2 but not in case 1 (fig. 1). CDAI scores were 606 at baseline and 408 after 
5 sessions of GMA in case 1, and 392 at baseline and 203 after 6 sessions of GMA in 
case 2.  
Discussion 
CD64, one of the Fc receptors for IgG, plays a role in antibody-dependent 
cytotoxicity, clearance of immune complexes, and phagocytosis of targets opsonized 
with IgG. It also mediates release of cytokines including IL-1, IL-6 and TNF-α. CD64 
is constitutively expressed on macrophages and monocytes and is upregulated on 
neutrophils as a physiological response to microbial wall components such as 
lipopolysaccharide (LPS), complement split products, and some cytokines such as 
IFN-γ and granulocyte colony-stimulating factor (G-CSF). Upregulation of CD64 
expression on neutrophils occurs 4–6 h after stimulation with IFN-γ, G-CSF or LPS 
[7, 13].  
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The expression of CD64 is elevated in patients with IBD compared to healthy 
subjects and correlates with clinical and biochemical disease variables. As reported 
earlier, clinical improvement after steroid therapy is reflected by downregulated CD64 
expression by polymorphonuclear leukocytes [14]. Therefore, CD64 expression is 
responsive to therapeutic interventions [15]. We investigated blood CD64 levels before 
and after GMA in CD patients, which was reduced after GMA. Further study will be 
needed to determine the effects of GMA on CD64 in ulcerative colitis.  
In conclusion, GMA reduced blood CD64 levels, which would be an important factor 







Fig. 1. CD64 levels before and after GMA in case 2. CD64 levels were significantly decreased after 
GMA treatment compared to those before GMA. 
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